Namely, so far, VGLL4 has been investigated as a therapeutical target in triple-negative breast cancer, lung cancer, colorectal cancer, and gastric cancer [41,46,57,58]. The gene discussed is VGLL4; the disease is triple-negative breast carcinoma.